胶质母细胞瘤
贝伐单抗
医学
肿瘤科
内科学
癌症研究
化疗
作者
Mehmet Beşiroğlu,Abdallah TM Shbair,Ayşe İrem Yasin,Atakan Topçu,Hacı Mehmet Türk,Tarık Demir
标识
DOI:10.29271/jcpsp.2021.01.39
摘要
Objective: To evaluate the predictive significance of systemic inflammation markers (SIMs) in patients with glioblastoma multiforme (GBM), who were treated with bevacizumab (Beva).Study Design: Descriptive study.
科研通智能强力驱动
Strongly Powered by AbleSci AI